Abstract
Tezepelumab (tezepelumab-ekko; TEZSPIRE (R)), a first-in-class monoclonal antibody targeting thymic stromal lymphopoietin, represents a novel, effecti......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
